PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: FTPB (French Technology Press Bureau)

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

BioMérieux Has Novel Solutions for Clinical Management of Sepsis - bioMérieux, a world leader in the field of in vitro diagnostics, offers a wide range of solutions to fight sepsis, the most common underlying cause of death in non-coronary intensive care units
BioMérieux Has Novel Solutions for Clinical Management of Sepsis

 

NewswireToday - /newswire/ - London, United Kingdom, 2009/02/16 - bioMérieux, a world leader in the field of in vitro diagnostics, offers a wide range of solutions to fight sepsis, the most common underlying cause of death in non-coronary intensive care units.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

This was illustrated by bioMérieux’s sponsoring of the Sepsis 2008 international symposium held in Spain last November.

Sepsis is a complex clinical syndrome that is defined as a systemic inflammatory response (SIRS) with presumed or confirmed bacterial infection (Source: Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ; Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis; The ACCP/SCCM Consensus Conference Committee; American College of Chest Physicians/Society of Critical Care Medicine; Chest. 1992; 101(6): 1644-55). The mortality rate in non-coronary intensive care units can be as high as 32% in cases of severe sepsis or 54% in cases of septic shock (Source: Vincent J-L, Sakr Y, Sprung CL, et al; Sepsis in European intensive care units: Results of the SOAP study; Crit Care Med 2006; 34: 344-355).

Early recognition and timely initiation of appropriate therapy is key to improving the outcome of patients with sepsis (Source: Dellinger RP, Carlet JM, Masur H, et al; Surviving Sepsis Campaign guidelines for the management of severe sepsis and septic shock; Crit Care Med 2004; 32: 858-873). By rapidly and accurately detecting the presence of microbial infection in SIRS patients, in vitro diagnostic tests can provide clinically relevant information and support early diagnosis of sepsis.

For bioMérieux, an expert in diagnostic solutions for infectious disease management, sepsis is a key area. The company has developed a broad range of solutions to support clinical diagnosis, prognosis and antibiotic stewardship for the management of sepsis. bioMérieux’s aim is to lead the way as a partner to healthcare professionals around the world in the fight against sepsis.

bioMérieux’s products span microbiology, immunoassay and molecular biology technologies. The extensive range includes BacT/ALERT® for blood cultures, VIDAS® B.R.A.H.M.S PCT for early detection and monitoring of severe bacterial infections, VITEK® 2 for automated identification and antibiotic susceptibility testing, and Etest®, a predefined gradient technique used to determine the on-scale Minimum Inhibitory Concentration (MIC) of antibiotics agents. bioMérieux also distributes AdvanDx rapid molecular tests – PNA FISH® – in the United States for species identification of bacteria and yeast from positive blood cultures (a procedure that takes less than three hours).

bioMérieux has been a sponsor of the valuable work undertaken by the International Sepsis Forum (ISF) group for many years, and actively participated in Sepsis 2008, an international symposium held in Granada (Spain) from 19 to 22 November 2008.

About bioMérieux
A world leader in the field of in vitro diagnostics for 45 years, bioMérieux (biomerieux.com) is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2007, group revenues reached €1.063 billion, with 84% of sales generated outside France.

bioMérieux provides diagnostic solutions (reagents, instruments and software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s products are used for diagnosing infectious diseases and providing high medical value results for cardiovascular emergencies and cancer screening and monitoring. They are also used for detecting micro-organisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the NYSE Euronext Paris market (Code: BIM – Code ISIN: FR0010096479).

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: FTPB (French Technology Press Bureau)

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


BioMérieux Has Novel Solutions for Clinical Management of Sepsis

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Biomérieux | FTPB
Publisher Contact: Kate Ambler - UBIFRANCE.fr 
+44(0)20 7235 5330 contact.ftpb[.]ubifrance.fr
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any FTPB (French Technology Press Bureau) securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From FTPB (French Technology Press Bureau) / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  BizJobs.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)